Galecto, Inc.GLTOEarnings & Financial Report
Galecto Biotech is a biotechnology company that develops small molecules for the treatment of severe diseases, including fibrosis, cancer and inflammation. The company was founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom, and Denmark. The company today is incorporated in the U.S., and has its operating headquarters in Copenhagen, Denmark.
GLTO Q4 FY2025 Key Financial Metrics
Revenue
$1.0M
Gross Profit
N/A
Operating Profit
$-201.7M
Net Profit
$-200.7M
Gross Margin
N/A
Operating Margin
-20149.5%
Net Margin
-20053.5%
YoY Growth
339.0%
EPS
$10.86
Galecto, Inc. Q4 FY2025 Financial Summary
Galecto, Inc. reported revenue of $1.0M (up 339.0% YoY) for Q4 FY2025, with a net profit of $-200.7M (down 2877.8% YoY) (-20053.5% margin).
Key Financial Metrics
| Total Revenue | $1.0M |
|---|---|
| Net Profit | $-200.7M |
| Gross Margin | N/A |
| Operating Margin | -20149.5% |
| Report Period | Q4 FY2025 |
Galecto, Inc. Annual Revenue by Year
Galecto, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $844.0K).
Galecto, Inc. Quarterly Revenue & Net Profit History
Galecto, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $1.0M | +339.0% | $-200.7M | -20053.5% |
| Q4 FY2024 | $228.0K | -32.9% | $-6.7M | -2956.6% |
| Q3 FY2024 | $146.0K | -69.1% | $-3.9M | -2659.6% |
| Q2 FY2024 | $213.0K | -51.8% | $-5.3M | -2506.1% |
| Q1 FY2024 | $257.0K | -40.8% | $-5.5M | -2131.1% |
| Q4 FY2023 | $340.0K | +19.7% | $-6.5M | -1904.4% |
| Q3 FY2023 | $473.0K | +114.0% | $-8.1M | -1720.1% |
| Q2 FY2023 | $442.0K | +183.3% | $-10.7M | -2430.8% |
Income Statement
| Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $442000 | $473000 | $340000 | $257000 | $213000 | $146000 | $228000 | $1.0M |
| YoY Growth | 183.3% | 114.0% | 19.7% | -40.8% | -51.8% | -69.1% | -32.9% | 339.0% |
Balance Sheet
| Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $58.8M | $50.0M | $38.2M | $32.5M | N/A | $23.4M | $17.1M | $260.5M |
| Liabilities | $15.1M | $12.7M | $5.9M | $4.3M | N/A | $2.4M | $1.3M | $20.1M |
| Equity | $43.7M | $37.4M | $32.3M | $28.2M | $23.6M | $20.9M | $15.8M | $240.4M |
Cash Flow
| Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-7.8M | $-8.5M | $-11.5M | $-5.9M | $-4.1M | $-3.7M | $-4.9M | $566000 |